New drugs for the old enemy

Learn how top pharma and CROs plan to speed database build and data collection, as well as their top challenges and future priorities. Join this webinar to gain insights into Taking an agile approach to database buildReducing user acceptance testing (UAT) timelines with a risk-based approach. Driving innovation at your organization. This in-depth research from Tufts follows their industry-wide eClinical Landscape Study, examining the major cause of database build delays and their impact on trial cycle times.

IIdiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias and life-threatening multi-organ dysfunction.

This webinar addresses the requirements for continuous monitoring of water for injection (WFI) systems and how this can be achieved with total organic carbon (TOC) and conductivity. It will also cover cold WFI production according to EP and how it applies to water systems.

Current diagnostic methods for lower respiratory specimens typically take one to two days to identify most bacterial pathogens. During that time, clinicians must rely on guideline recommendations and clinical diagnosis to guide empiric therapy, which is not optimized based on the patient’s individual pathogen. The BioFire Pneumonia Panel will provide pathogen identification in a much shorter timeframe and may allow clinicians to optimize targeted pathogen-specific therapy sooner. The BioFire Pneumonia Panel is a rapid multiplex-PCR test that identifies 33 targets, including 18 bacteria, 8 viruses and 7 antimicrobial resistance genes from lower respiratory tract specimens in about an hour. It provides semi-quantitative results (in copies/ml) for 15 of the bacterial targets. This new feature provided by multiplex-PCR testing may help clinicians and laboratorians separate colonizing from pathogenic levels of bacteria.